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Abstract
Background: Many patients with chronic obstructive pulmonary disease (COPD) suffer from exacerbations, a worsening of
their respiratory symptoms that warrants medical treatment. Exacerbations are often poorly recognized or managed by patients,
leading to increased disease burden and health care costs.
Objective: This study aimed to examine the effects of a smart mobile health (mHealth) tool that supports COPD patients in the
self-management of exacerbations by providing predictions of early exacerbation onset and timely treatment advice without the
interference of health care professionals.
Methods: In a multicenter, 2-arm randomized controlled trial with 12-months follow-up, patients with COPD used the smart
mHealth tool (intervention group) or a paper action plan (control group) when they experienced worsening of respiratory symptoms.
For our primary outcome exacerbation-free time, expressed as weeks without exacerbation, we used an automated telephone
questionnaire system to measure weekly respiratory symptoms and treatment actions. Secondary outcomes were health status,
self-efficacy, self-management behavior, health care utilization, and usability. For our analyses, we used negative binomial
regression, multilevel logistic regression, and generalized estimating equation regression models.
Results: Of the 87 patients with COPD recruited from primary and secondary care centers, 43 were randomized to the intervention
group. We found no statistically significant differences between the intervention group and the control group in exacerbation-free
weeks (mean 30.6, SD 13.3 vs mean 28.0, SD 14.8 weeks, respectively; rate ratio 1.21; 95% CI 0.77-1.91) or in health status,
self-efficacy, self-management behavior, and health care utilization. Patients using the mHealth tool valued it as a more supportive
tool than patients using the paper action plan. Patients considered the usability of the mHealth tool as good.
Conclusions: This study did not show beneficial effects of a smart mHealth tool on exacerbation-free time, health status,
self-efficacy, self-management behavior, and health care utilization in patients with COPD compared with the use of a paper
action plan. Participants were positive about the supportive function and the usability of the mHealth tool. mHealth may be a
valuable alternative for COPD patients who prefer a digital tool instead of a paper action plan.
Trial Registration: ClinicalTrials.gov NCT02553096; https://clinicaltrials.gov/ct2/show/NCT02553096.
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Introduction
Exacerbations in chronic obstructive pulmonary disease (COPD)
are acute events of transient worsening of the respiratory
condition. Exacerbations considerably affect patients’ health
status [1,2], accelerate the decline in lung function [3], and
contribute to COPD-related costs [4]. Despite the substantial
impact that exacerbations may have, patients with COPD often
have difficulty in recognizing symptom deterioration [5] and
do not respond timely or adequately in the course of symptom
worsening [6].
Self-management strategies, such as the use of a written
exacerbation action plan, have been shown to improve
exacerbation outcomes, that is, decrease exacerbation duration
[7,8], reduce hospital admissions [9,10], and decrease the impact
on health status [10,11]. However, many patients do not adhere
to the self-management instructions in their action plans when
an exacerbation is imminent [7,12] and thus do not get the
benefit of the favorable health effects of timely detection and
subsequent intervention.
Telemonitoring, in which patients record and send information
on symptoms or physiological measurements to a supervising
clinician, may be an alternative approach to self-management
strategies to reduce the impact of COPD exacerbations.
Beneficial effects have been reported on the number of hospital
admissions [13], emergency visits [13], and quality of life in
some studies [14,15] but not in all [16]. There is much
heterogeneity between telemonitoring interventions regarding
devices and clinical content, and the amount of additional
support that patients receive. However, in contrast with
self-management, telemonitoring strongly depends on the
judgement of the clinician and the patient is not expected to
interpret his or her own symptoms and signs. Therefore, we
have developed [17] and validated [18] an innovative mobile
health (mHealth) tool, called the Adaptive Computerized COPD
Exacerbation Self-management Support system. This tool aims
to tailor self-management support more efficiently and
continuously than with a written action plan but without heavily
increasing the involvement of health care professionals to
monitor input, as is the case with telemonitoring. The mHealth
tool integrates information on symptom changes and
physiological measurements (ie, pulse oximetry, spirometry,
and measurement of body temperature) in an easy-to-use app
by means of a mobile phone [17]. On the basis of a decision
tree built by a clinical expert panel and a Bayesian prediction
model, the tool provides automated, tailored self-management
advice to the patient without the involvement of a health care
professional [18]. Patients can use the tool at their own initiative
to monitor symptom changes at any time of day or night and
receive ad hoc, tailored advice.
In this study, we examined the clinical effectiveness of the
mHealth tool. We hypothesized that in patients with COPD, the
use of the tool would lead to more weeks without exacerbations;
improvement in health status, self-efficacy, and
self-management behavior; and a reduction in health care
utilization compared with the use of a paper exacerbation action
plan. We also evaluated how patients valued the tool’s
supportive function and usability.
Methods
Study Design
This study was a multicenter, parallel, 2-arm, randomized
controlled trial with a follow-up of 12 months per patient. After
signing informed consent, patients with COPD recruited from
general practices and outpatient clinics followed a 20-min
self-management educational group session primarily addressing
early recognition and prompt treatment of exacerbations.
Subsequently, patients were randomized to either (1) usual care
according to current COPD guidelines, that is, exacerbation
self-management support through the use of a paper
exacerbation action plan (control group) or (2) exacerbation
self-management support through the use of the mHealth tool
(intervention group). Participants in the control group were
provided with a written action plan if they did not have one.
Participants in the intervention group were instructed not to use
their action plan if they had one before participation. This study
has been registered at ClinicalTrials.gov (Identifier:
NCT02553096) and has been approved by the medical ethics
review board, region Arnhem-Nijmegen, the Netherlands (file
2014-1270).
Setting and Participants
Patients were recruited between June 2015 and July 2016 at the
pulmonary outpatient clinics of 3 Dutch hospitals and 9 general
practices in the city of Nijmegen and the surroundings in the
Netherlands. All participating centers delivered care according
to the current Dutch COPD guideline [19] and had a pulmonary
or practice nurse available for COPD care. Patients were eligible
for participation if they (1) were aged at least 40 years, (2) had
a spirometry-confirmed diagnosis of COPD (postbronchodilator
forced expiratory volume in 1 second (FEV1)/forced vital
capacity<0.7), and (3) had experienced 2 or more
symptom-based exacerbations in the previous 12 months,
defined as a change for greater than or equal to 2 consecutive
days in either greater than or equal to 2 major symptoms
(dyspnea, sputum purulence, and sputum amount) or any 1
major symptom plus greater than or equal to 1 minor symptoms
(colds, wheeze, sore throat, and cough) [3,20]. Exclusion criteria
were (1) severe comorbid conditions that prohibited safe
participation, (2) insufficient knowledge of the Dutch language,
and (3) persisting difficulties in using the mHealth system after
a 2-week practice period and additional assistance.
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Randomization Procedure
We used a computer-generated 2-block randomization
procedure, stratifying for the health care center. All patients
from the participating centers who met the inclusion criteria
received a questionnaire from their health care professional with
questions related to exacerbations in the previous 12 months.
Patients who responded and had experienced 2 or more
symptom-based exacerbations in the previous 12 months (see
inclusion criteria) were invited by the research team to
participate in this study. The allocation order was determined
by the order in which eligible patients responded to our
invitation to participate (kept by the research assistant).
Participants were assigned to one of the groups after signing
informed consent during the group meeting by the researcher
(LB). Owing to the type of intervention, patients and health care
professionals could not be blinded for group assignment. In
addition, the research team could not be blinded as it was
responsible for the personalization and technical support of the
mHealth tool. The study statistician (RA) who was responsible
for analyzing the data was blinded for study assignment of the
participants until the analyses had been finished.
Intervention and Control Group
Before randomization and after signing the written informed
consent, all participants received a 20-min educational session
based on the Dutch version of the Living Well with COPD
self-management program provided by the nurse in groups of
4 to 10 participants to establish a homogeneous baseline in
exacerbation self-management knowledge [12].
Participants in the intervention group were instructed to visit
the nurse within 2 weeks after allocation for instructions on the
use of the mHealth tool. The tool consisted of a mobile phone
(provided by the research team), a pulse oximeter (CMS50D,
Contec Medical Systems,), a spirometer (PiKo-1 monitor,
nSpire), and a forehead thermometer (FTN, Medisana AG).
Patients answered 12 yes-or-no questions concerning changes
in symptoms, physical limitations, and emotions using the touch
screen on the mobile phone complemented by measurements
with the pulse oximeter, spirometer, and forehead thermometer
(see Multimedia Appendix 1) [17]. All questions had to be
answered to proceed. On the basis of a built-in Bayesian network
decision model, the mHealth tool then provided one or more of
the following advices: (1) increase your bronchodilator use
(including a personalized medication instruction), (2) use your
breathing techniques, (3) use your coughing techniques, (4) be
thoughtful of how you distribute your energy during the day,
(4) contact your health care professional today, (5) measure
again tomorrow. Completing the questions and measurements
took approximately 5 min. The mHealth tool has been developed
in close collaboration with COPD patients and health care
professionals [17] and has shown high sensitivity and specificity
[18].
Before the trial started, participants in the intervention group
were instructed to use the system daily for 2 weeks to get
familiarized with the app, mobile phone, spirometer, pulse
oximeter, and forehead thermometer. Data were sent to a secured
Web-based interface and were monitored by the research team
to make sure participants practiced sufficiently. After this
2-week run-in period, the nurses evaluated patients’ use of the
system, including the physiological measurements. Reference
values for each patient’s FEV1 and peripheral oxygen saturation
were set. Then, the 12-month follow-up period started. Patients
were instructed to use the tool every time they experienced or
had any doubts about any change in symptoms or disease
burden.
Participants in the control group visited the nurse within 2 weeks
of allocation for instructions on the use of a paper exacerbation
action plan. When patients did not already possess a written
action plan at that moment, the nurses provided the action plan
of the Living Well with COPD program [12]. The plan consisted
of instructions regarding the self-management of an
exacerbation, for example, increase the use of bronchodilators,
initiate a standing prescription for a course of prednisolone
and/or antibiotic treatment if applicable, or contact the health
care professional within 3 days of symptom aggravation.
At the 3-month follow-up, patients in both the intervention and
control groups were invited by their nurse to evaluate their
self-management of COPD exacerbations. In the intervention
group, only the nurses received the patients’ entries in the
mHealth tool from the research team to enable tailoring of
feedback on self-management behavior. In the control group,
the nurses evaluated the use of the paper action plan. Patients
in both the groups did not receive any feedback on
self-management behavior before or after this nurse contact.
All patients in both the intervention and control groups
continued to have complete access to their health care
professionals during the follow-up.
Outcomes and Follow-Up
Our primary outcome was the difference in the number of
exacerbation-free weeks between the intervention and control
groups. An exacerbation-free week was defined as a week in
which there had not been episodes of 2 or more consecutive
days with worsening of 2 major symptoms (ie, dyspnea, sputum
purulence, and sputum amount) or 1 major and 1 or more minor
symptoms (ie, colds, wheeze, sore throat, and cough) [21].
Symptom changes were assessed using the Telephonic
Exacerbation Assessment System (TEXAS, Radboudumc), an
automated telephone call system that contacted participants
weekly on the day and time of their preference [22]. TEXAS
consisted of closed questions regarding changes in respiratory
symptoms, use of health care resources, and use of respiratory
medication in the week before the call, and its validity has been
demonstrated previously [22]. Owing to the discontinuation of
the contract with the provider of TEXAS, the last 19 participants
in the trial received a weekly online questionnaire containing
the same questions as TEXAS. These participants used both
measuring tools during 2 weeks before stopping with TEXAS,
which enabled us to compare data entries from TEXAS with
the online survey tool. We found no differences in the data
entries.
The secondary outcomes included the following:
• Exacerbation-related outcomes, that is, the number of
unscheduled health care contacts, the number of
exacerbations treated with antibiotics and/or prednisolone,
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and the number of exacerbation-related hospital admissions,
all retrieved from patients’ medical records, and the number
of symptom-based exacerbations as assessed with TEXAS.
• Exacerbation-related self-management behavior, measured
with TEXAS or the online questionnaire, and defined as
taking 1 or more of the following 3 actions during
symptom-based exacerbations: (1) contacting the health
care professional, (2) starting a course of prednisolone
and/or antibiotics, or (3) maximizing bronchodilator use.
We also assessed the time between the date of exacerbation
onset and the date of 1 of these 3 actions, defining actions
taken within 3 days of exacerbation onset as adherence to
the instructions.
• Exacerbation-related self-efficacy, measured with an
exacerbation-related self-efficacy scale containing 5
questions. This questionnaire was created for the purpose
of this study as, to our knowledge, no questionnaire existed
that measured exacerbation-related self-efficacy. Reliability
analyses showed a Cronbach alpha of .69 at baseline and
.81 at follow-up.
• Health status, measured with (1) the Nijmegen Clinical
Screening Instrument (NCSI), which is a battery of
instruments measuring 8 subdomains of health
status—subjective symptoms, dyspnea emotions, fatigue,
behavioral impairment, subjective impairment, general
quality of life (QoL), health-related QoL, and satisfaction
with relationships [23]; (2) the Clinical Chronic Obstructive
Pulmonary Disease Questionnaire (CCQ), which measures
3 subdomains, that is, symptoms, functional status, and
mental status, resulting in a total score (24); and (3) the
EuroQol-5 dimensions (EQ-5d), [24], which measures
health-related quality of life, with a total score based on
weighted scores on mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression as well as a vertical
Visual Analogue Scale varying between 0 and 100.
At the start and at 12 months, data were gathered on
exacerbation history, self-efficacy, and health status. CCQ and
EQ-5d were also completed at 3, 6, and 9 months of follow-up.
At 12 months, information on health care utilization, lung
function, respiratory medication use, and comorbid conditions
was extracted from the participants’ medical records. In addition,
all participants were asked to evaluate the supportive function
of either the mHealth tool or the paper action plan by using a
paper survey including closed-ended questions regarding the
use, difficulty in use, and intended future use of the mHealth
tool or the paper action plan. Besides, 3 questions were asked
related to clarity, suitability, and follow-up of the advice given
by the mHealth tool or the paper action plan. All questions
included answers on a 7-point rating scale from strongly disagree
(score 1) to strongly agree (score 7). The survey also included
1 question about frequency of usage at times of symptom
worsening, with answers on a 7-point rating scale varying from
1=never to 7=always. In addition, participants of the intervention
group were asked to complete the System Usability Scale (SUS)
[25]. The SUS contains 10 questions on system usability, which
are calculated into 1 total score between 0 and 100. SUS scores
less than 68 are considered as low, greater than or equal to 68
and less than or equal to 80.3 as good, and greater than 80.3 as
excellent.
Sample Size Calculation and Statistical Analyses
Sample size calculation using analysis of variance showed that
we needed 43 participants in each group for 80% power
(alpha=.05, 2 sided) to detect an increase of 6 exacerbation-free
weeks per year and anticipating a dropout rate of 20% (9/43).
The calculation was based on a previous dataset [12] in which
we found a mean of 44 exacerbation-free weeks, with SD 4.5
weeks. We used all available data from all participants based
on the intention-to-treat principle. Missing data were not
imputed.
We used the data recorded by the secured Web-based interface
to assess the actual usage of the mHealth tool. We analyzed the
answers to the paper evaluation survey to assess participants’
self-reported use of the mHealth tool and the paper action plan.
Negative binomial regression analyses, controlling for follow-up
time per participant, age and gender were used to analyze our
primary outcome, that is, the number of exacerbation-free weeks,
as well as the number of unscheduled health care contacts,
self-reported exacerbations, exacerbations treated with
antibiotics and/or prednisolone, and exacerbation-related
hospital admissions.
To test the effect of the mHealth tool on the rate of
symptom-based exacerbations and self-management behavior,
we extracted exacerbation episodes from the TEXAS database.
Each new episode was preceded by at least 2 exacerbation-free
weeks or 2 weeks with missing data [22]. To assess patient
delay in taking action when an exacerbation was imminent, the
numbers of days were calculated between the date of
exacerbation onset and the following actions: (1) the first date
of contact with a health care professional, (2) starting date of
the course of prednisolone and/or antibiotics, or (3) date of
increase of bronchodilators. We categorized these variables into
2 groups: less than 3 days (according to instructions), and greater
than or equal to 3 days. Separate multilevel logistic regression
analyses were performed taking into account the clustering
effect of exacerbations within patients and controlling for age
and gender to examine (1) whether the mHealth tool led to
higher percentages of self-management actions in case of an
exacerbation compared with the paper action plan and (2)
whether these actions were more often taken timely by patients
in the intervention group compared with the control group.
We used generalized estimating equation regression analyses
to estimate the effect of the mHealth tool on changes between
baseline and follow-up scores of the self-efficacy scale, NCSI,
CCQ, and EQ-5d compared with the paper action plan. We
analyzed the CCQ and EQ-5d with all 5 measurement time
points. We used 2-tailed t tests for independent samples and
chi-square test to analyze the differences in the participants’
preferences between the mHealth tool and the paper action plan.
Statistical significance was assumed at P<.05 based on 2-sided
tests. We used IBM SPSS Statistics 25 for the analyses.
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Results
Patient Characteristics
Of the 87 patients included in the study, 43 were randomized
to the intervention group. In addition, 45 patients were recruited
from the hospitals and 42 from the general practices. Among
them, 13% (11/87) dropped out of the study, 16% (7/43) in the
intervention, and 9% (4/44) in the control group. A flowchart
of the participants in the study is shown in Figure 1.
Demographic and baseline characteristics are shown in Table
1.
Mean duration of follow-up was 48.1 (SD 11.7) weeks, and 11
COPD-related hospital admissions (6 in the intervention group
and 5 in the control group) were reported as serious adverse
events to the medical ethics review board.
Usage of Mobile Health Tool and Paper Action Plan
From the Web-based interface, it appeared that 38 of the 43
patients (88%) in the mHealth group used the app 727 times in
total during follow-up. No data on usage was available for 5
patients. The range in frequency of usage was 1 to 250 times
with a median of 7 (25%-75% interquartile range was 3-14).
Results of the evaluation questionnaire showed that more
patients reported to have used their mHealth tool often (scores
6 and 7 on the 7-point rating scale) compared with patients in
the control group who reported to have used their paper action
plan (44.4% vs 17.2%, respectively).
Figure 1. Flow diagram of the participants through the study. mHealth: mobile health.
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Table 1. Baseline and demographic characteristics of the study population (N=87) per treatment arm.
Paper action plan control group (n=44)Mobile health tool intervention group (n=43)Characteristic
24 (55)21 (49)Recruited in hospital, n (%)
49.8 (10.9)48.3 (12.6)Follow-up in weeks, mean (SD)
65.9 (8.9)69.3 (8.8)Age (years), mean (SD)
29 (66)25 (58)Male sex, n (%)
52.1 (19.8)53.0 (21.5)Postbronchodilator FEV1a (% predicted), mean (SD)
2.6 (1.3)2.5 (1.2)Medical Research Council dyspnea score, mean (SD)
11 (25)13 (30)Currently smoking, n (%)
17 (39)11 (26)Use of paper action plan prior to follow-up, n (%)
Respiratory drug treatment, n (%)
26 (59)27 (63)Long-acting bronchodilators
31 (71)30 (70)Short-acting bronchodilators
13 (30)7 (16)Inhaled corticosteroids (ICS)
24 (55)22 (51)Long-acting bronchodilators + ICS
17 (39)19 (44)Low education level, n (%)
28 (64)29 (68)Diagnosis of COPD >5 years, n (%)
10 (23)6 (14)Currently working, n (%)
Relevant comorbidities, n (%)
13 (30)13 (30)Joint disorders
12 (27)12 (28)Cardiac disorders
14 (32)8 (19)Back pain
3 (7)3 (7)Diabetes
2 (5)3 (7)Depression and/or anxiety
aFEV1: forced expiratory volume in 1 second.
Table 2. Comparison of exacerbation-related outcomes between intervention group and control group (N=85).
P valueRate ratio (95% CI)aPaper action plan con-
trol group (n=44),
mean (SD)
Mobile health tool in-
tervention group
(n=41), mean (SD)
Outcome
.401.21 (0.77-1.90)28.0 (14.8)30.6 (13.3)Exacerbation-free weeksb
.700.89 (0.50-1.60)1.6 (2.0)1.6 (1.7)Unscheduled health care consultations because of respiratory
complaintsc
.801.07 (0.65-1.75)4.3 (2.1)4.5 (2.3)Symptom-based exacerbationsb
.971.01 (0.53-1.93)1.0 (1.3)1.1 (1.5)Exacerbations treated with antibiotics and/or prednisolonec
.741.25 (0.35-4.44)0.14 (0.41)0.15 (0.43)Exacerbation-related hospital admissionsc
aCalculated using negative binomial regression analyses, relative to participants’ follow-up time, controlling for age and gender.
bData retrieved from weekly patient reports.
cData retrieved from patient medical files.
Exacerbation-Free Time and Other
Exacerbation-Related Outcomes
Patients in the intervention group did not differ statistically
significantly from patients in the control group in the number
of weeks without exacerbations (mean 30.6 weeks, SD 13.3
weeks vs mean 28.0 weeks, SD 14.8 weeks, respectively; rate
ratio [RR] 1.21; 95% CI 0.77-1.91; see Table 2). In addition,
no statistically significant differences were found in the number
of symptom-based exacerbations (mean 4.5, SD 2.3 vs mean
4.3, SD 2.1, respectively; RR 1.07, 95% CI 0.65-1.75), and the
number of exacerbations treated with antibiotics and/or
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prednisolone (mean 1.0, SD 1.5 vs mean 1.0, SD 1.3,
respectively; RR 1.01, 95% CI 0.53-1.93). Furthermore, no
statistically significant between-group differences were found
in the number of unscheduled health care contacts (mean 1.6,
SD 1.7 vs mean 1.6, SD 2.0, respectively; RR 0.89, 95% CI
0.50-1.60) and exacerbation-related hospital admissions (mean
0.15, SD 0.43 vs mean 0.14, SD 0.41, respectively; RR 1.25,
95% CI 0.35-4.44).
Self-Management Behavior
A total of 377 symptom-based exacerbation episodes were
identified. Table 3 shows that there were no statistically
significant differences between the intervention and control
groups in the frequency of contacting a health care professional
(odds ratio [OR] 0.94, 95% CI 0.51-1.73), initiating a course
of antibiotics and/or prednisolone (OR 1.16, 95% CI 0.55-2.44),
and increasing bronchodilator use (OR 1.08, 95% CI 0.56-2.06).
We found no differences between the intervention and control
groups in timely action, that is, contacting a health care
professional (OR 2.21, 95% CI 0.78-6.23), starting a course of
antibiotics and/or prednisolone (OR 1.46, 95% CI 0.48-4.42),
or increasing bronchodilator use (OR 1.15, 95% CI 0.61-2.16)
within 3 days of exacerbation onset (Table 4).
Self-Efficacy and Health Status
We found no statistically significant difference in
exacerbation-related self-efficacy between the intervention and
control groups when comparing baseline scores with 12-month
follow-up scores. In addition, there were no differences between
the groups in changes between baseline and follow-up scores
of the subscales of the NCSI, CCQ and EQ-5d (Table 5).
Participant Evaluation of the Self-Management
Support Tools
A total of 58 (67%) participants returned an evaluation form,
of which 28 were in the intervention group. The mHealth tool
was rated as a more useful support tool than the paper action
plan (P=.02). No differences were found between the mHealth
tool and the action plan in the self-reported frequency of use;
in difficulty and future use of the tool; or in clarity, suitability,
and follow-up of the advice. Overall, 26 participants of the
intervention group completed all 10 questions of the SUS. The
mean score was 78.5 (SD 14.4).
Table 3. Self-reported self-management behavior during exacerbation onset (N=377 exacerbations).
P valueOdds ratio (95% CI)aPaper action plan control
group (n=190), n (%)
Mobile health tool intervention
group (n=187), n (%)
Self-management action
.830.94 (0.51-1.73)68 (35.8)61 (32.6)Contact health care professional
.691.16 (0.55-2.44)62 (32.6)64 (34.2)Start prednisolone and/or antibiotics
.821.08 (0.56-2.06)135 (71.1)135 (72.2)Increase bronchodilator use
aCalculated using multilevel logistic regression analyses, including participant as cluster variable, controlling for age and gender.
Table 4. Self-reported self-management behavior within 3 days of exacerbation onset.
P valueOdds ratio (95% CI)aPaper action plan control
group
Mobile health tool intervention
group
Self-management action
<3 days, n (%)n<3 days, n (%)n
.132.21 (0.78-6.23)17 (27.0)6320 (36.4)55Contact health care professional
.501.46 (0.48-4.42)23 (40.4)5723 (39.7)58Start prednisolone and/or antibiotics
.671.15 (0.61-2.16)80 (68.4)11787 (71.3)122Increase bronchodilator use
aCalculated using multilevel logistic regression analyses, including participant as cluster variable, controlling for age and gender.
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Table 5. Baseline and follow-up scores of exacerbation-related self-efficacy and measures of health status.
P valuePaper action plan control groupMobile health tool intervention groupOutcome
Beta (95% CI)a12-month
(n=41), mean
(SD)
Baseline
(n=44), mean
(SD)
12-month (n=35),
mean (SD)
Baseline (n=43),
mean (SD)
.910.03 (−0.17 to 0.22)2.87 (0.52)2.84 (0.41)2.98 (0.41)2.91 (0.43)Exacerbation-related self-efficacyb
Health status measurementsc
.192.53 (−1.28 to −6.33)17.11 (12.14)19.08 (11.93)13.01 (8.27)12.90 (8.32)NCSId QOLe
.66−0.16 (−0.89 to −0.57)4.76 (1.93)4.68 (1.78)4.00 (1.61)4.19 (1.74)NCSI HRQOLf
.290.30 (−0.26 to −0.85)3.24 (1.59)3.39 (1.74)2.58 (0.87)2.42 (0.93)NCSI relationship
.50.74 (−1.38 to −2.85)13.22 (6.57)14.41 (6.57)11.20 (4.12)11.84 (5.80)NCSI subjective impairment
.52−1.77 (−7.20 to −3.66)20.43 (21.76)19.11 (17.28)20.50 (15.58)22.11 (17.89)NCSI behavioral impairment
.690.35 (−1.40 to −2.11)11.05 (4.79)11.91 (4.86)9.23 (4.39)9.86 (4.88)NCSI subjective symptoms
.240.85 (−0.58 to −2.27)10.73 (4.32)11.59 (3.92)8.71 (2.86)8.77 (2.42)NCSI dyspnea emotions
.33−1.80 (−5.43 to −1.84)37.73 (10.20)37.32 (10.17)35.23 (9.45)35.93 (10.96)NCSI fatigue
.7−0.06 (−0.38 to −0.26)2.16 (1.05)2.31 (1.09)1.84 (0.77)2.06 (1.02)CCQg total
.34−0.22 (−0.67 to −0.23)2.49 (1.24)2.60 (1.27)2.16 (0.80)2.41 (1.12)CCQ symptoms
.760.05 (−0.30 to −0.40)2.41 (1.32)2.53 (1.36)2.03 (1.21)2.22 (1.38)CCQ functional status
.680.09 (−0.34 to −0.53)1.00 (1.05)1.30 (0.99)0.81 (0.79)1.03 (1.01)CCQ mental status
.22−0.05 (−0.13 to −0.03)0.77 (0.21)0.74 (0.20)0.79 (0.16)0.81 (0.15)EQ-5dh
.076.28 (−0.56 to −13.11)62.63 (19.14)64.20 (15.35)70.94 (12.92)65.53 (17.37)EQ VASi
aBeta (B) indicates the difference between the intervention and control groups on differences between baseline and at 12 months.
bHigher score is positive.
cHigher score is negative.
dNCSI: Nijmegen Clinical Screening Instrument.
eQOL: quality of life.
fHRQOL: health-related quality of life.
gCCQ: Clinical Chronic Obstructive Pulmonary Disease Questionnaire.
hEQ-5d: EuroQol-5 dimensions.
iEQ VAS: EuroQol Visual Analogue Scale.
Discussion
Principal Findings
In this study, we examined the clinical effects of a smart
mHealth tool to support COPD patients in the detection and
treatment of exacerbations without the interference of a health
care professional. Our primary hypothesis that the use of
mHealth would lead to more weeks without exacerbations than
care as usual, that is, the use of a paper action plan, was not
confirmed. In addition, we did not find differences in
exacerbation frequency, health care utilization, or
self-management behavior between patients who used the
mHealth tool and patients who used the paper action plan.
Furthermore, patients using the tool did not report higher
exacerbation-related self-efficacy or better health status than
patients using a paper action plan. Patients evaluated the
usability of the mHealth tool as good and considered it as more
supportive than the action plan.
Comparison With Previous Work
So far, studies on the effects of electronic health (eHealth) in
the management of COPD have focused on the use of
telemonitoring apps [26,27]. However, the mHealth tool in our
study critically differs from telemonitoring tools as it enables
the patient to be solely responsible for initiating treatment,
without the interference of a health care professional. This
impedes comparing our results with those found in
telemonitoring trials. A recent Cochrane review showed that,
until now, there is only limited evidence that interventions aimed
at facilitating, supporting, and sustaining self management in
patients with COPD and delivered via smart technology may
improve outcomes such as health status and physical activity
[28]. We found no effects of the mHealth tool on health status,
measured with generic questionnaires, such as the NCSI and
the EQ-5D, or with a disease-specific questionnaire, such as the
CCQ.
In this study, we could not demonstrate positive effects on
exacerbation-free weeks, exacerbation frequency, and health
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care utilization. Our primary outcome, exacerbation-free weeks,
is directly related to exacerbation recovery time and may better
reflect the burden of exacerbations in patients with COPD than
exacerbation frequency does [21]. The mean number of
exacerbation-free weeks we found during the 1-year follow-up
period was 30.6 weeks in the intervention group and 28.0 weeks
in the control group. These mean values are in line with the 33.4
weeks that we found in a previous study in which we examined
the relationship between exacerbation frequency and
exacerbation-free time in a cohort of 166 COPD patients [21].
These values suggest that there was enough room for
improvement as the participants seem to suffer from symptom
worsening in approximately 20 weeks in the 1-year follow-up
period. Although patients rated the mHealth tool as a more
useful support tool than the paper action plan, we found no
differences between the mHealth tool and the paper action plan
on self-management behavior and exacerbation-related
self-efficacy. Previous studies showed that patients with COPD
were able to use mHealth apps, including reporting daily
symptoms and measuring physiological variables [29], and were
able to interpret clinical data and use these within their
self-management approach regardless of previous knowledge
[30]. These findings are in line with our finding that participants
in the intervention group rated the usability of the mHealth tool
as good on average.
Limitations
The major strength of this study is that we used a well-designed
and validated mHealth tool to support self-management behavior
[18]. In a qualitative study, Korpershoek et al demonstrated that
to optimize engagement, mHealth interventions should be
attractive, rewarding, safe, and tailored to the patient needs [31].
Our mHealth tool has been developed using feedback from
patients with COPD, and its treatment advice can be tailored to
the individual patient. To further optimize the use of the tool,
patients were familiarized with the technique during a 2-week
run-in period.
However, this study also has limitations. Two important
limitations may have led to the statistically nonsignificant results
of our primary outcome exacerbation-free weeks. First, we were
surprised that the mean exacerbation-free time and its standard
deviation at the 12-month follow-up differed substantially from
the study data on which our power calculation was based [12].
We cannot explain this. As a result, the sample size in this study
may have been too small to actually detect any statistically
significant differences in our primary outcome. Conversely,
when we performed our sample size calculation, there were no
other studies available to provide data on exacerbation-free
time. Second, offering both the intervention and control groups
a short education session on the recognition and treatment of
exacerbations before the start of the study and providing a paper
action plan to the control group may have reduced the room for
improvement and may have diluted potential differences
between the 2 groups on our primary outcome exacerbation-free
weeks. The purpose of the education session was to equalize
the level of self-management knowledge among all participants
and between both groups before the start of the trial. Our choice
may have upgraded self-management knowledge and skills of
all participants, although we did not measure what the
participants had actually learned from the session to verify this
assumption. We chose to provide our control group with a paper
action plan according to the recommendations in the current
national COPD guideline [19]; thereby supporting the
self-management knowledge and skills of the control group
participants. Many general practitioners and chest physicians
in the Netherlands have not (yet) integrated the use of paper
action plans in their daily practice. This was also found in our
study, in which only 25.6% participants of the intervention
group and 38.6% participants of the control group used a paper
action plan before the study. Conversely, previous use of a paper
action plan could have affected our primary outcome
exacerbation-free weeks if patients in the intervention group
continued to use the paper action plan instead of using the
mHealth tool. Although we cannot refute this assumption with
our data, we think that this effect (if any) has been small as we
found that all intervention group participants used the mHealth
tool and that more patients in the intervention group used the
mHealth tool than patients in the control group used their paper
plans.
There are also other limitations. Of the 467 patients that
responded to the study invitation and met the inclusion criteria,
283 were not willing to participate. This may have led to
selection bias. We believe that the risk of contamination because
of the individual randomization procedure is negligible, as both
the mHealth tool and the paper action plan were used at home,
outside the reach of the health care professional. Although in
the last 4 months of the trial we had to switch to collecting
exacerbation-related outcomes through a digital survey tool
instead of the automated TEXAS telephone calls [22], this did
not impact the rate of data entry, and the participants
experienced no difficulties. So, although it was an undesirable
deviation from the protocol, we have no concerns on the
reliability of the primary outcome data. Finally, 12 months of
follow-up may have been too short for the mHealth tool to reach
its maximum effect, as it may take more time to sustain
engagement with the technology and change self-management
behavior [28].
Future Research
Although we were not able to demonstrate positive effects of
our mHealth tool, we still believe that the use of eHealth tools,
including machine learning techniques, better suits the goals of
patient-centered care and self-management support than
telemonitoring tools where a health care professional monitors
the patient from a distance. Besides, in this study, the patients
using the mHealth tool evaluated it as usable and more
supportive than patients using a conventional supportive tool,
that is, the written paper action plan. Future research should
focus more on patients who are specifically interested in using
digital tools in their daily life, as these patients may have greater
benefit from them [28]. More information on patient perceptions
of the use of the mHealth tool is also needed and could be
collected by patient interviews or open-ended surveys. In
addition, more research is needed on the clinical effects of the
mHealth tool when used appropriately and the factors that are
associated with appropriate use. However, for these purposes,
there is a need for studies with larger patient populations than
in this study.
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Conclusions
In this study, we examined the effectiveness of an mHealth tool
designed to support COPD patients in their self-management
of symptom worsening to reduce the impact of exacerbations.
The app was not designed to replace the health care professional
but to reduce patient delay. Patients evaluated the app’s usability
as good and as more supportive than the paper action plan.
Although this study did not show beneficial effects of the
mHealth app compared with the use of a paper action plan,
based on patient’s preference, it may be a valuable alternative
to a paper action plan in the management of COPD.
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